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Introduction {#sec006}
============

Cognitive impairment has been reported to occur in 40--65% of patients with multiple sclerosis (MS) and can present even in early phases of the disease \[[@pone.0221784.ref001]--[@pone.0221784.ref004]\]. We have previously reported the profile of cognitive decline in a large cohort of 1500 MS patients showing that cognitive performance was below the normative average for cognitively intact individuals of similar age and education, with information processing speed and executive function most frequently impaired \[[@pone.0221784.ref005]\]. Cognitive impairment was significant only at disease duration greater than five years suggesting the existence of an early therapeutic window \[[@pone.0221784.ref005]\]. However, the effects of disease modifying drugs (DMD) on cognitive impairments in MS have not been thoroughly studied \[[@pone.0221784.ref006]\], though several DMD have demonstrated a beneficial effect on cognitive performance \[[@pone.0221784.ref007]\] and spared brain atrophy \[[@pone.0221784.ref008]--[@pone.0221784.ref010]\], thus showing the potential to decrease cognitive decline.

Progression of cognitive decline in MS over time is variable, and it is not yet clear why some patients are cognitively resilient, while others decline within a short period of time. Prevalence of cognitive resilience in MS may explain variability across patients in profile of cognitive decline, and such resilience may signify a less active or even benign disease, and/or improved ability to recover during the active disease process.

In the current study, we characterized cognitive performance in DMD treated MS patients with disease duration longer than 10 years. We computed prevalence of patients with high, moderate and low cognitive performance and evaluated the relationship between cognitive status and neurological disability.

Methods {#sec007}
=======

Study design and participants {#sec008}
-----------------------------

This was a retrospective analysis of cross-sectional data obtained from RRMS and SPMS patients treated and followed at the Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Israel. Demographic, clinical and cognitive data were extracted from the Sheba MS Center computerized database. The following criteria were applied to extract data for the current analyses: Inclusion criteria: (1) diagnosis of definite MS according to the revised McDonald criteria \[[@pone.0221784.ref011]\]; (2) cognitive assessment after at least 10 years from disease onset; (3) neurological examination with Expanded Disability Status Scale (EDSS) \[[@pone.0221784.ref012]\] within 3 months of the cognitive assessment; (4) treatment with DMD for at least 6 moths. Exclusion criteria: (1) primary progressive disease course; (2) corticosteroid treatment up to 3 months prior to the cognitive assessment; (3) known psychiatric illnesses (including major depression or anxiety) or dementia; (4) alcohol or drug abuse; (5) severe impairment of the upper limbs and/or visual impairment precluding performance of the computerized cognitive assessment. This was determined as a part of the cognitive test. Patients with severe upper limb dysfunction like paralysis or tremor that were not able to hold the computer-mouse were technically excluded from preforming the test. Similarly, at the beginning of the cognitive test visual acuity is assessed and patients that could not read the instructions were technically excluded from performing the test.

Each patient record was coded anonymously to ensure confidentiality during statistical analyses. For patients with multiple cognitive assessments, an automated algorithm randomly selected data from one visit so that each patient is represented only once in the study dataset. The study was approved by the Sheba Medical Center IRB Ethics Committee.

Cognitive assessment {#sec009}
--------------------

Cognitive performance was assessed with a battery of computerized tests (NeuroTrax Corporation, Medina, NY, USA). The NeuroTrax cognitive battery has been previously validated in MS patients showing good discriminant and construct validity as compared to conventional cognitive assessment \[[@pone.0221784.ref003], [@pone.0221784.ref013]\], and incorporates alternate forms that minimize learning on follow‐ups. The battery is easily administered, and testing included the following cognitive domains: memory (verbal and nonverbal), executive function, attention, information processing speed, visual spatial processing, verbal function and motor skills. Each cognitive score was standardized relative to age-/education-stratified cognitively intact norms and scaled to an IQ-style scale (mean: 100, SD: 15). Domain scores were computed as the average scores from particular tests (see \[[@pone.0221784.ref003],[@pone.0221784.ref005]\] for more details). A global cognitive score (GCS) was computed as the average of the cognitive domains scores. Testing time was approximately 45 min. The computerized cognitive battery has shown good test-retest reliability and construct validity relative to paper-based tests, including the frequently used Neuropsychological Screening Battery for MS, NSBMS, \[[@pone.0221784.ref003]\], as well as sensitivity to effects of DMD in MS \[[@pone.0221784.ref007]\].

Group categorization {#sec010}
--------------------

Cognitive performance was categorized by GCS as "high" (GCS \>100), "moderate" (GCS 85--100) or "low" (GCS\<85). Neurological disability was classified according to EDSS score as "mild" (EDSS ≤3), \"moderate" (EDSS 3.5--5.5), or \"severe\" (EDSS ≥6.0).

Statistical analysis {#sec011}
--------------------

Descriptive statistics were used to summarize demographic, clinical and cognitive variables. Between groups differences were evaluated by the chi-square test for categorial variables and by analysis of variance (ANOVA) for [continuous variable](https://www.statisticshowto.datasciencecentral.com/continuous-variable/)s. Analyses were carried out using SPSS Version 25.0 (IBM Corporation, Armonk, NY, USA). Two-tailed statistics were used, and significance level was set to p\<0.05.

Results {#sec012}
=======

We analyzed data obtained from 1010 relapsing-remitting (RRMS) and secondary-progressive (SPMS) patients, 700 females, 310 males, mean age 49.3 (SD = 11.0) years, all treated with DMD for a mean period of 9.2 (SD = 5.6) years. Demographic, neurologic and cognitive data subdivided by cognitive performance group are shown in [Table 1](#pone.0221784.t001){ref-type="table"}. After a mean disease duration of 19.6 (SD = 7.7) years, low cognitive performance was found in 23.7% (N = 239) of patients, moderate performance in 42.7% (N = 431), and 33.7% (N = 340) had high cognitive performance attaining scores above average for cognitively intact individuals of similar age and education. Generally, lesser cognitive impairment was associated with lesser disability ([Fig 1](#pone.0221784.g001){ref-type="fig"}). As expected, significant differences between the low, moderate and high cognitive groups were found for all cognitive measures. Neurological disability by EDSS score and the functional system disability scores (except for visual functional score) were significantly higher in the groups with low and moderate cognitive performance as compared to patients with high cognitive performance.

![Correlation between cognitive performance and disability.](pone.0221784.g001){#pone.0221784.g001}

10.1371/journal.pone.0221784.t001

###### Demographic and clinical data for MS patients with long disease duration subdivided by cognitive performance.

![](pone.0221784.t001){#pone.0221784.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                 Cognitive performance   p-value                                    
  ------------------------ ----------------------- -------------- ------------- ------------- -----------------------------------------------------------------------------------------------------------------------------------
  Count (%)                \                       340 (33.7)     431 (42.7)    239 (23.7)    
                           1010                                                               

  Age, y                   49.3 (11.0)             49.2 (11.0)    49.7 (11.3)   48.6 (10.4)   0.423

  Gender                                                                                      

      Female, n            700                     219            318           163           0.017[\*^a^](#t001fn002){ref-type="table-fn"}^,^[^b^](#t001fn003){ref-type="table-fn"}^,^[^c^](#t001fn004){ref-type="table-fn"}

      Male, n              310                     121            113           76            

  MS Type (RR/SP)          812/198                 298/42         352/79        162/77        \<0.001[\*^a^](#t001fn002){ref-type="table-fn"}^,^[^c^](#t001fn004){ref-type="table-fn"}

  Disease duration, y      19.6 (7.7)              18.6 (6.9)     19.8 (8.2)    20.8 (7.8)    0.113

  Education, y             14.5 (2.4)              15.0 (2.5)     14.3 (2.3)    14.0 (2.4)    \<0.001[\*^a^](#t001fn002){ref-type="table-fn"}^,^[^c^](#t001fn004){ref-type="table-fn"}

  DMD treatment\           9.2 (5.6)               9.2 (5.5)      9.2 (5.6)     9.1 (5.6)     0.979
  duration, y                                                                                 

  EDSS                     3.8 (2.2)               2.8 (2.0)      3.8 (2.2)     5.1 (2.1)     \<0.001[\*^a^](#t001fn002){ref-type="table-fn"}^,^[^b^](#t001fn003){ref-type="table-fn"}^,^[^c^](#t001fn004){ref-type="table-fn"}

      Pyramidal            2.3 (1.4)               1.7 (1.3)      2.3 (1.4)     3.0 (1.3)     \<0.001[\*^a^](#t001fn002){ref-type="table-fn"}^,^[^b^](#t001fn003){ref-type="table-fn"}^,^[^c^](#t001fn004){ref-type="table-fn"}

      Cerebellar           1.3 (1.2)               0.8 (0.9)      1.3 (1.1)     2.0 (1.2)     \<0.001[\*^a^](#t001fn002){ref-type="table-fn"}^,^[^b^](#t001fn003){ref-type="table-fn"}^,^[^c^](#t001fn004){ref-type="table-fn"}

      Brainstem            0.6 (0.9)               0.4 (0.7)      0.5 (0.8)     1.0 (1.0)     \<0.001[\*^a^](#t001fn002){ref-type="table-fn"}^,^[^c^](#t001fn004){ref-type="table-fn"}

      Sensory              1.1 (1.2)               0.8 (1.0)      1.2 (1.2)     1.4 (1.2)     \<0.001[\*^a^](#t001fn002){ref-type="table-fn"}^,^[^b^](#t001fn003){ref-type="table-fn"}^,^[^c^](#t001fn004){ref-type="table-fn"}

      Bowel & Bladder      1.3 (1.2)               0.9 (1.0)      1.3 (1.2)     1.8 (1.3)     \<0.001[\*^a^](#t001fn002){ref-type="table-fn"}^,^[^b^](#t001fn003){ref-type="table-fn"}^,^[^c^](#t001fn004){ref-type="table-fn"}

      Visual               0.4 (0.9)               0.4 (0.9)      0.4 (0.9)     0.5 (1.0)     0.245

      Cerebral             0.3 (0.8)               0.1 (0.4)      0.3 (0.8)     0.6 (1.1)     \<0.001[\*^a^](#t001fn002){ref-type="table-fn"}^,^[^b^](#t001fn003){ref-type="table-fn"}^,^[^c^](#t001fn004){ref-type="table-fn"}

  Global cognitive score   92.8 (14.0)             106.2 (4.0)    93.6 (4.3)    72.4 (9.9)    \<0.001[\*^a^](#t001fn002){ref-type="table-fn"}^,^[^b^](#t001fn003){ref-type="table-fn"}^,^[^c^](#t001fn004){ref-type="table-fn"}

      Memory               92.9 (17.9)             105.2 (6.6)    95.0 (11.8)   71.6 (19.0)   \<0.001[\*^a^](#t001fn002){ref-type="table-fn"}^,^[^b^](#t001fn003){ref-type="table-fn"}^,^[^c^](#t001fn004){ref-type="table-fn"}

      Executive function   93.0 (15.8)             106.8 (8.7)    92.6 (8.6)    73.7 (13.3)   \<0.001[\*^a^](#t001fn002){ref-type="table-fn"}^,^[^b^](#t001fn003){ref-type="table-fn"}^,^[^c^](#t001fn004){ref-type="table-fn"}

      Visual spatial       97.8 (18.9)             110.6 (1.4)    96.6 (15.4)   81.2 (19.8)   \<0.001[\*^a^](#t001fn002){ref-type="table-fn"}^,^[^b^](#t001fn003){ref-type="table-fn"}^,^[^c^](#t001fn004){ref-type="table-fn"}

      Verbal function      93.6 (20.4)             104.4 (8.4)    94.8 (15.4)   73.3 (27.2)   \<0.001[\*^a^](#t001fn002){ref-type="table-fn"}^,^[^b^](#t001fn003){ref-type="table-fn"}^,^[^c^](#t001fn004){ref-type="table-fn"}

      Attention            91.9 (17.3)             104.9 (6.3)    93.7 (9.2)    69.4 (17.4)   \<0.001[\*^a^](#t001fn002){ref-type="table-fn"}^,^[^b^](#t001fn003){ref-type="table-fn"}^,^[^c^](#t001fn004){ref-type="table-fn"}

      Processing speed     93.6 (17.9)             107.4 (12.0)   91.3 (12.6)   71.2 (12.9)   \<0.001[\*^a^](#t001fn002){ref-type="table-fn"}^,^[^b^](#t001fn003){ref-type="table-fn"}^,^[^c^](#t001fn004){ref-type="table-fn"}

      Motor skills         92.2 (17.2)             104.2 (8.9)    91.3 (12.7)   71.3 (17.7)   \<0.001[\*^a^](#t001fn002){ref-type="table-fn"}^,^[^b^](#t001fn003){ref-type="table-fn"}^,^[^c^](#t001fn004){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GCS = Global cognitive score; DMD = Disease modifying drugs

\*^a^between high and low cognitive performance

^b^between low and moderate cognitive performance

^c^between high and moderate cognitive performance.

No significant differences between cognitive performance groups were observed for age and DMD treatment duration.

The relationship between cognitive performance and disability status in the entire cohort ([Fig 2](#pone.0221784.g002){ref-type="fig"}), further elucidates the association between disability and cognitive decline.

![Cognitive performance in relation to disability levels.](pone.0221784.g002){#pone.0221784.g002}

Among patients with high cognitive performance, 64.4% (219/340) had mild disability and can therefore be considered to have a benign MS disease pattern under DMD treatment. Among patients with moderate cognitive performance, 44% (190/431) had mild disability, and among patients with low cognitive performance, 50.6% (121/239) had a high level of disability. Analysis of patients with 'inconsistency' between cognitive performance and disability status demonstrated that 4.5% (46/1010) had high cognitive performance in spite of severe disability, while 5.0% (50/1010) had low cognitive performance in spite of mild disability. The majority of patients with high cognitive performance and severe disability had SPMS and more years of education as compared to patients with low cognitive performance and mild disability, and the difference between these groups could not be accounted for by DMD treatment duration, [Table 2](#pone.0221784.t002){ref-type="table"}.

10.1371/journal.pone.0221784.t002

###### Groups with 'inconsistency' between cognitive performance and disability.

![](pone.0221784.t002){#pone.0221784.t002g}

  -------------------------------------------------------------------------------------------------------------------
  Variable                    Low cognitive performance & Mild disability   High cognitive performance &\   p-value
                                                                            Severe disability               
  --------------------------- --------------------------------------------- ------------------------------- ---------
  Number                      50                                            45                              

  Age, y                      47.2 (10.0)                                   56.6 (8.4)                      0.082

  Gender (F/M)                38/12                                         29/16                           0.191

  MS type (RR/SP)             49/1                                          11/34                           \<0.001

  Disease duration, y         19.5 (6.8)                                    23.7 (8.1)                      0.789

  Education, y                13.8 (2.2)                                    15.6 (2.5)                      0.002

  DMD treatment duration, y   8.7 (5.2)                                     10.4 (5.1)                      0.120
  -------------------------------------------------------------------------------------------------------------------

Data are presented as mean (SD)

Discussion {#sec013}
==========

Our study assessed the frequency of cognitive impairment in a large cohort of DMD- treated RRMS and SPMS patients after nearly 20 years of illness. Notably, we observed a much lower rate of cognitive impairment than previously reported in the literature. Most studies assessing cognitive performance in MS estimated frequency of cognitive decline, particularly in the domains of attention, processing speed and working memory, to be within the range of 40% to 60% over the lifespan, but these studies were performed mainly in patients who did not receive DMD \[[@pone.0221784.ref004], [@pone.0221784.ref014]\]. It is not surprising that cognitive impairment would be less than in the pre-DMD treatment era, due to effective disease modification and greater ascertainment of milder cases of MS.

The use of DMD significantly changed the pattern of MS progression. These medications modulate the inflammatory immune response and lead to decreased disease activity by reducing relapse rate and delaying disability progression. Consequently, these treatments lead to better cognitive protection \[[@pone.0221784.ref015]\]. The safety-risk profile of DMD in MS is favorable. Possible side effects vary between treatments and include injection-site reactions, increased risk for infections, gastrointestinal symptoms, flushing, autoimmune thyroid disorders and elevated liver enzymes \[[@pone.0221784.ref016]\].

In our cohort of patients treated with DMD for a relatively long period, only 23.7% had low cognitive performance, while 33.7% had high cognitive performance attaining scores above average for cognitively intact individuals of similar age and education. This group of patients, that after a long disease duration of almost 20 years, maintained their cognitive skills, can be defined as 'cognitively resilient' patients. The term resilience is derived from the Latin words salire (to leap or jump), and resilire (to spring back). When applied to cognition it denotes the capacity of the brain to resist deteriorating processes or injuries \[[@pone.0221784.ref017],[@pone.0221784.ref018]\]. Cognitive resilience literature has focused on specific contexts in which individuals differ in their capabilities to withstand or overcome brain insults and to explain the difference in the patterns of cognitive decline associated with aging and neurodegenerative diseases \[[@pone.0221784.ref019]\]. Various predisposing interacting factors may contribute to the road map for brain resilience, including education, gender, prior brain injuries, family history, participation in cognitively stimulating activities, physical exercise, social relationships and apoE genotype \[[@pone.0221784.ref020]--[@pone.0221784.ref024]\]. In young patients with a chronic long-lasting disease like MS, characterizing differences between cognitive subgroups in relation to clinical variables may afford new insights into active neuroplasticity mechanisms and thus suggest plasticity facilitating treatments to enhance cognitive resilience. Our findings suggest a reason for optimism relative to the previously reported studies. Furthermore, we found that approximately 75% of RRMS and SPMS patients (i.e., "moderate" and "high" cognitive performance groups combined) do not have low levels of cognitive function that may compromise quality of life, social interactions, employment prospects and work performance \[[@pone.0221784.ref025]\].

It is of note that different DMD may have varying effects on cognitive performance, that during the long-term study period, patients switched DMD, and that treatment duration under each DMD varied; however, in spite of these limitations that make it difficult to assess the contribution of each DMD to cognitive performance, our findings are encouraging in suggesting that overall, long-term treatment with DMD affords significant beneficial effects in the maintenance of normal brain function.

As anticipated, increased neurological disability correlated with lower cognitive performance, indicating that cognitive function is an integral clinical feature of MS and directly related to neurological disability. Neurological disability by the EDSS score and functional system disability scores were significantly higher in the groups with low and moderate cognitive performance as compared to patients with high cognitive performance. No difference was found for visual functional score between the groups, probably because visual impairment was an exclusion criterion. However, no significant differences between high, moderate and low cognitive performance groups were observed for age and DMD treatment duration, suggesting that differences in cognitive performance may be attributable to differential disease activity. More aggressive disease activity characterized by increased rate of relapses and post-relapse residual disability \[[@pone.0221784.ref026]\] may lead to worse cognitive performance and higher disability despite treatment with DMD; this more aggressive group comprised 12.0% of the cohort. In contrast, 21.7% of the patients had high cognitive performance and low level of disability and can therefore be considered to have benign MS \[[@pone.0221784.ref027], [@pone.0221784.ref028]\]. Cognitive resilience in these patients probably signifies MS resilience, e.g., resilience to the disease pathogenic mechanisms. These patients have low disability and therefore also manifest with less cognitive impairment, suggesting that cognition as a part of the functional neurological spectrum of MS, is better preserved in patients with less active disease. Indeed, it is expected that patients with a benign disease course, probably presenting as good responders to DMD treatment, will be resilient to disability and cognitive decline even after many years of disease.

More intriguing is to understand the groups for which cognitive performance and disability were inconsistent, i.e., patients who after a long-term follow-up present with high cognitive performance and severe disability (4.5%), or patients with low cognitive performance and mild disability (5.0%). We believe that these minority groups may have a different anatomical pattern of central nervous system involvement. Patients with cognitive resilience but severe disability probably have more pronounced spinal cord involvement, either cervical, thoracic or both \[[@pone.0221784.ref029]\], while patients with low cognitive performance and mild disability likely will have more distinct brain atrophy and a higher brain lesion load, with lesser cervical or thoracic spinal cord involvement \[[@pone.0221784.ref030], [@pone.0221784.ref031]\].

In our cohort, 33.7% of patients were cognitively resilient. These patients had intact cognitive performance despite an extended disease duration, and the majority were also neurologically protected, reflected by a relatively low EDSS score. One of the mechanisms that accounts for cognitive resilience may be preserved brain functional reserve. In accordance, Rocca et al., \[[@pone.0221784.ref032]\] reported that relatively mild grey matter damage was associated with a favorable clinical course in patients with benign MS. Sumowski et al., \[[@pone.0221784.ref033]\] have suggested that the level of cerebral efficiency prior to disease affords a 'cognitive reserve' against disease-related cognitive impairment, such that when cognitive processing is challenged by a brain disease, individuals with greater cerebral efficiency are better able to withstand the insult and will not develop cognitive impairment. Indeed, in our cohort, educational level was higher in patients with high cognitive performance as compared to patients with moderate and low cognitive performance.

Although our study is retrospective and cross-sectional and included only relapsing-remitting and secondary progressive patients, it encompasses a large number of patients, and to the best of our knowledge, this is the first study that evaluates "real-world" experience of DMD treatments on cognitive performance in MS patients. We could not evaluate the effects of individual DMD on cognitive performance as patients changed treatments, and the treatment period for each medication varied. However, the main strength of our study is in elucidating the relationship between cognitive performance and disability in MS patients after a long disease duration.

We suggest that pre-disease intellectual enrichment reflected by educational level contributes to better cognitive reserve and better cognitive resilience in MS patients. Furthermore, a cognitive sparing effect can be enhanced by DMD treatment leading to a high rate of MS patients without cognitive decline even after many years from onset.

The authors thank Roi Aloni, Keren Gutman and Tali Paz for their field work that greatly contributed to this research project.

Eli Simon passed away before the submission of the final version of this manuscript. Anat Achiron accepts responsibility for the integrity and validity of the data collected and analyzed.
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Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Sep 22 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Abiodun E. Akinwuntan, PhD, MPH, MBA

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

Good job responding to the comments. Consistency in terminologies has made the manuscript easier to read and understand.

The few corrections needed are:

Page 6: Consider adding \"disability\" in the sentence with: Neurological disability by EDSS score and the functional system \"disability\" scores (except for visual functional score) were .....

Page 6, last paragraph: Table 2 shows 45/1010 while the narrative reports 45/1010 for high cognitive performance and severe disability. Which is correct?

Page 7, second paragraph in \"Discussion\": Consider changing the sentence to \"The use of DMD significantly changed the pattern of MS progression.\"

Overall, check all citations and references for accuracy.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Thank you for the opportunity to evaluate the manuscript PONE-D-19-14839R1 "Cognitive function in multiple sclerosis: a long-term look on the bright side". I was not involved in the first review round and will therefore critique the manuscript from a fresh perspective.

This retrospective study includes a large number (n = 1010) of patients with relapsing-remitting multiple sclerosis (MS) and secondary progressive MS. The main aim was to describe cognitive functioning in those patients who had received at least 10 years of disease modifying drug treatment and to correlate cognitive impairments with long term disability. The authors found that the majority of patients with MS did not have cognitive decline. The authors discuss the findings in light of cognitive resilience and long-term quality of life.

Overall, I enjoyed reading the manuscript. The manuscript is topical, timely, and well-written and contributes to the body of knowledge. My major comments are:

1\. The discussion around cognitive resilience could be strengthened. Devote at least a paragraph explaining what cognitive resilience is, how it can be captured, what predisposing factors contribute to cognitive resilience, and how that may impact disability and quality of life. Provide references.

2\. The leap from good performance on cognitive tests to "cognitive resilience" needs better argumentation. The authors report that 33.7% are cognitive resilient because they score well on cognitive tests despite long disease duration. However, they also have mild disability. It is logical to assume that those with mild disability will also have less cognitive impairments. The 33.7% with good performance in cognitive tests reported here do well because they are generally less disabled; not necessarily because they show better cognitive resilience. You could also argue then that these individuals have better physical resilience, or respond better to disease modifying treatment. It would be more important to focus on the persons who show high cognitive performance despite moderate to severe disability, e.g., those individuals reported in Table 2.

I have few minor comments:

3\. How were the three groups of cognitive performance and the three groups of neurological disability determined. Please provide references on the categorization of cognitive performance and neurological disability.

4\. Please add in the limitations section that this study included only relapsing-remitting and secondary progressive MS.

5\. Please elaborate on exclusion criterion 5. How was it determined from chart review whether a patient had severe upper limb or visual impairment?

6\. On that note, visual performance did not differ between the three groups (Table 1), probably because visual impairment was an exclusion criterion. Please add this to the discussion.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Hannes Devos

\*\*\*\*\*\*\*\*\*\*

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0221784.r004

Author response to Decision Letter 1

10 Aug 2019

Comment 1. Page 6: Consider adding \"disability\" in the sentence with: Neurological disability by EDSS score and the functional system \"disability\" scores (except for visual functional score) were .....

Response: Corrected

Comment 2. Page 6, last paragraph: Table 2 shows 45/1010 while the narrative reports 45/1010 for high cognitive performance and severe disability. Which is correct?

Response: The title column in Table 2 shows: High cognitive performance & Severe disability, so essentially both are the same and correct.

Comment 3. Page 7, second paragraph in \"Discussion\": Consider changing the sentence to \"The use of DMD significantly changed the pattern of MS progression.\"

Response: corrected.

Comment 4. check all citations and references for accuracy.

Response: We checked all citations and references to ensure accuracy.

Review Comments to the Author

1\. The discussion around cognitive resilience could be strengthened. Devote at least a paragraph explaining what cognitive resilience is, how it can be captured, what predisposing factors contribute to cognitive resilience, and how that may impact disability and quality of life. Provide references.

Response: We have added to the Discussion a paragraph explaining what cognitive resilience is, how it can be captured, what predisposing factors contribute to cognitive resilience, and how that may impact disability and quality of life. In accordance we have provide references as follows:

The term resilience was derived from the Latin words salire (to leap or jump), and resilire (to spring back). When applied to cognition it stands for the capacity of the brain to resist deteriorating processes or injuries (SternY. What is cognitive reserve? Theory and research applications of the reserve concept. J Int Neuropsychol Soc 2002; 8:448--460. McEwen BS. In pursuit of resilience: stress, epigenetics, and brain plasticity. Ann N Y Acad Sci. 2016;1373:56-64). Cognitive resilience literature has focused on specific contexts in which individuals differ in their capabilities to withstand or overcome brain insults and to explain the difference in the patterns of cognitive decline associated with aging and neurodegenerative diseases (de Frias CM, Dixon RA, Bäckman L. Use of memory compensation strategies is related to psychosocial and health indicators. J Gerontol B Psychol Sci Soc Sci. 2003;58:12-22.). Various predisposing interacting factors may contribute to the road map for brain resilience including education, gender, prior brain injuries, family history, participation in cognitively stimulating activities, physical exercises, social relationships and apoE genotype. (Christensen H1, Hofer SM, Mackinnon AJ, Korten AE, Jorm AF, Henderson AS. Age is no kinder to the better educated: absence of an association investigated using latent growth techniques in a community sample. Psychol Med. 2001;31:15-28. Kirk-Sanchez NJ, McGough EL. Physical exercise and cognitive performance in the elderly: current perspectives. Clin Interv Aging. 2014;9:51-62. Hofer SM, Christensen H, Mackinnon AJ, Korten AE, Jorm AF, Henderson AS, Easteal S. Change in cognitive functioning associated with apoE genotype in a community sample of older adults. Psychol Aging. 2002;17:194-208. Wilson RS, Mendes De Leon CF, Barnes LL, Schneider JA, Bienias JL, Evans DA, Bennett DA. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA. 2002;287:742-8. Seeman TE, Lusignolo TM, Albert M, Berkman L. Social relationships, social support, and patterns of cognitive aging in healthy, high-functioning older adults: MacArthur studies of successful aging. Health Psychol. 2001;20:243-55.). In young patients with a chronic long-lasting disease like MS, characterizing differences between cognitive subgroups in relation to clinical variables may afford new insights into the on-going neuroplasticity mechanisms and in accordance suggest plasticity‐facilitating treatments to enhance cognitive resilience.

2\. The leap from good performance on cognitive tests to "cognitive resilience" needs better argumentation. The authors report that 33.7% are cognitive resilient because they score well on cognitive tests despite long disease duration. However, they also have mild disability. It is logical to assume that those with mild disability will also have less cognitive impairments. The 33.7% with good performance in cognitive tests reported here do well because they are generally less disabled; not necessarily because they show better cognitive resilience. You could also argue then that these individuals have better physical resilience, or respond better to disease modifying treatment. It would be more important to focus on the persons who show high cognitive performance despite moderate to severe disability, e.g., those individuals reported in Table 2.

Response: As the Reviewer commented, indeed, cognitive resilience in patients with long disease duration and mild disability probably signifies MS resilience, e.g., resilience to the disease pathogenic mechanisms. These patients are defined as patients with benign disease course and therefore also manifest with less cognitive impairments. Our findings implicate that cognition as a part of the functional neurological spectrum of MS is better reserved in patients with less active disease, as patients with low disability were found to be more cognitively resilient.

Regarding the group of patients who show high cognitive performance despite moderate to severe disability as compared to patients with low cognitive performance despite mild disability, we have specified in the Discussion a possible explanation related to anatomical involvement. We suggest that patients with moderate to severe disability but high cognitive performance the spinal cord will be more involved as compared to patients with mild disability but with low cognitive performance that probably present widespread brain disease and relatively lower spinal cord involvement.

We have added these paragraphs to the Discussion.

minor comments:

3\. How were the three groups of cognitive performance and the three groups of neurological disability determined. Please provide references on the categorization of cognitive performance and neurological disability.

Response: As specified in the Methods - Cognitive assessment, last paragraph, the three groups of cognitive performance and the three groups of neurological disability were determined according to the global cognitive score (GCS) and the Expanded Disability Status Scale (EDSS) score as follows:

Cognitive performance was categorized by GCS as "high" (GCS \>100), "moderate" (GCS 85-100) or "low" (GCS\<85). Neurological disability was classified according to EDSS score as "mild" (EDSS ≤3), \"moderate" (EDSS 3.5-5.5), or \"severe\" (EDSS \>6.0).

Both are referenced.

We better detailed this by adding the title of Group categorization to this paragraph.

4\. Please add in the limitations section that this study included only relapsing-remitting and secondary progressive MS.

Response: Added.

5\. Please elaborate on exclusion criterion 5. How was it determined from chart review whether a patient had severe upper limb or visual impairment?

Response: This exclusion criteria is determined as a part of the cognitive test. Patients that have severe upper limb dysfunction like paralysis or tremor are not able to hold the computer-mouse and therefore are technically excluded from preforming the test. Similarly, at the beginning of the cognitive test visual acuity is assessed and patients that can not read the instructions are technically excluded from performing the test.

The explanation was added to exclusion criterion 5.

6\. On that note, visual performance did not differ between the three groups (Table 1), probably because visual impairment was an exclusion criterion. Please add this to the discussion.

Response: Added.

10.1371/journal.pone.0221784.r005
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Cognitive function in multiple sclerosis: A long-term look on the bright side

PONE-D-19-14839R2

Dear Dr. ACHIRON,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Abiodun E. Akinwuntan, PhD, MPH, MBA

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have adequately addressed all comments and I recommend moving forward with publication of this manuscript.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Hannes Devos

10.1371/journal.pone.0221784.r006
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Cognitive function in multiple sclerosis: A long-term look on the bright side

Dear Dr. ACHIRON:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Abiodun E. Akinwuntan

Academic Editor

PLOS ONE
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